| Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis I Parodis, C Adamichou, S Aydin, A Gomez, N Demoulin, ... Rheumatology 59 (11), 3424-3434, 2020 | 54 | 2020 |
| Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus I Parodis, P Johansson, A Gomez, S Soukka, S Emamikia, ... Rheumatology 58 (12), 2170-2176, 2019 | 42 | 2019 |
| Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus A Gomez, V Qiu, A Cederlund, A Borg, J Lindblom, S Emamikia, Y Enman, ... Frontiers in Medicine 8, 651249, 2021 | 38 | 2021 |
| Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus I Parodis, E Åkerström, C Sjöwall, A Sohrabian, A Jönsen, A Gomez, ... International Journal of Molecular Sciences 21 (10), 3463, 2020 | 29 | 2020 |
| Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus A Gomez, F Hani Butrus, P Johansson, E Åkerström, S Soukka, ... Rheumatology 60 (3), 1260-1272, 2021 | 26 | 2021 |
| Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies I Parodis, S Emamikia, A Gomez, I Gunnarsson, RF van Vollenhoven, ... Expert opinion on biological therapy 19 (2), 157-168, 2019 | 25 | 2019 |
| Smoking reduces the efficacy of belimumab in mucocutaneous lupus I Parodis, A Gomez, M Frodlund, A Jönsen, A Zickert, C Sjöwall, ... Expert opinion on biological therapy 18 (8), 911-920, 2018 | 25 | 2018 |
| Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus S Emamikia, S Oon, A Gomez, J Lindblom, A Borg, Y Enman, E Morand, ... Rheumatology 61 (12), 4752-4762, 2022 | 23 | 2022 |
| Aged blood factors decrease cellular responses associated with delayed gingival wound repair MP Saldías, C Fernández, A Morgan, C Díaz, D Morales, F Jana, ... PLoS One 12 (9), e0184189, 2017 | 21 | 2017 |
| Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials I Parodis, S Emamikia, A Gomez, C Gentline, EV Arkema, ... The Lancet Rheumatology 1 (3), e163-e173, 2019 | 20 | 2019 |
| EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus J Lindblom, A Gomez, A Borg, S Emamikia, D Ladakis, J Matilla, M Pehr, ... Rheumatology 60 (10), 4703-4716, 2021 | 16 | 2021 |
| Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE A Borg, A Gomez, A Cederlund, F Cobar, V Qiu, J Lindblom, S Emamikia, ... Rheumatology 60 (9), 4205-4217, 2021 | 14 | 2021 |
| Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. B Hernandez-Breijo, A Gomez, S Soukka, P Johansson, I Parodis Autoimmunity Reviews 18 (10), 102372-102372, 2019 | 14 | 2019 |
| Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis I Parodis, A Gomez, A Tsoi, JW Chow, D Pezzella, C Girard, TA Stamm, ... RMD open 9 (3), e003297, 2023 | 13 | 2023 |
| Established organ damage reduces belimumab efficacy in systemic lupus erythematosus I Parodis, A Gomez, S Emamikia, K Chatzidionysiou Annals of the Rheumatic Diseases 78 (7), 1006-1007, 2019 | 13 | 2019 |
| Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials A Gomez, S Jägerback, C Sjöwall, I Parodis Rheumatology 63 (2), 338-348, 2024 | 11 | 2024 |
| Use of antimalarial agents is associated with favourable physical functioning in patients with systemic lupus erythematosus A Gomez, S Soukka, P Johansson, E Åkerström, S Emamikia, Y Enman, ... Journal of Clinical Medicine 9 (6), 1813, 2020 | 11 | 2020 |
| Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature A Gomez, I Parodis Autoimmunity Reviews 21 (11), 103188, 2022 | 10 | 2022 |
| Early B cell and plasma cell kinetics upon treatment initiation portend flares in systemic lupus erythematosus: A post-hoc analysis of three phase III Clinical trials of belimumab I Parodis, A Gomez, JW Chow, A Borg, J Lindblom, M Gatto Frontiers in immunology 13, 796508, 2022 | 8 | 2022 |
| EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus J Lindblom, S Zetterberg, S Emamikia, A Borg, G von Perner, Y Enman, ... Frontiers in Medicine 9, 1092325, 2022 | 7 | 2022 |
Ioannis ParodisAdjunct lecturer, Karolinska InstitutetVerified email at ki.se
